Cell and gene therapy supply chain tracking software specialist TrakCel and The Quick Life Science Group have formed a partnership to offer an integrated IT logistics orchestration platform that enables cell and gene therapy companies to track products and manage the logistical processes of each needle-to-needle supply chain through a single interface. The platform enables automatic scheduling of activities across multiple supply chain partners, product-specific workflows to ensure consistent handling and execution of tasks, and validated chain-of-identity tracking to guarantee correct drug product delivery for clinics and manufacturing sites in North America and Europe.
According to the Alliance for Regenerative Medicine, there are 892 companies and 1003 industry-sponsored clinical trials underway worldwide utilising regenerative medicine and advanced cell therapy technologies. As a result, the volume and growth of clinical and commercial products is increasing the workload for all stakeholders across the supply chain including clinical sites, apheresis collection centres, manufacturing facilities and couriers. In addition, individual cell and gene therapy supply chains face unique complexities such as precise scheduling requirements and the need to transport temperature and time-sensitive materials globally. Therefore, a combination of these factors increases the necessity for control and visibility of the timing of sample collection through to product infusion and the new collaboration between TrakCel and Quick has been formed to address this.
Latest from Tom Mulligan
- EVENT PREVIEW: CPhI North America opens next week!
- NEW BUSINESS: SK biotek and AMPAC Fine Chemicals have ambitious CDMO plans
- NEW TECHNOLOGY: Polyplus-transfection develops GMP-grade therapeutic virus reagent
- Mogrify raises $3.7 million seed funding to support direct cellular conversion for cell therapy
- Owlstone Medical partners with Shanghai Renji Hospital to pioneer Breath Biopsy lung cancer trial
- Chemspace and LabNetwork collaborate to extend access to chemical databases
- TECHNOLOGY UPDATE: Catalent invests over $27 million to commercialise next-generation ODT Zydis Ultra
- SGS reports successful Phase 2 results for novel influenza vaccine, validating its H3N2 A/Belgium challenge agent
- NEW TECHNOLOGY: Horizon Discovery and Rutgers University develop new gene editing approach: ‘base editing’
- EVENT REVIEW: Busy sessions at BIO-Europe Spring!